Literature DB >> 2945860

Demonstration that human B cells respond differently to interleukin 2 and B cell differentiation factor based on their stages of maturation.

T Nakagawa, N Nakagawa, H Goldstein, D J Volkman, A S Fauci.   

Abstract

The mechanisms whereby interleukin 2 (IL 2), interferon-gamma (IFN-gamma), and B cell differentiation factor (BCDF) alone or in combination modulate human B cell differentiation are currently under intensive study. To dissect out the effects of individual lymphokines contained in mixed lymphocyte reaction-culture supernatants (MLR-CS) on B cell differentiation, we employed pure factors that possessed the same activity as factors contained in MLR-CS (IL 2: 50 U/ml, IFN-gamma: 7 U/ml, BCDF-Nal: 5 pM/ml, BCDF-YA2: 12.5% v/v) singly and in combination to human B cells. By activating purified human B cells with Staphylococcus aureus Cowan I (SAC) for 3 days, separating B blast cells by the Percoll centrifugation method, and then either using these B blast cells as B cells in the earlier stage after SAC-activation, or further culturing these B blast cells for 4 more days without any stimuli and using these B cells as B cells in the later stage after SAC-activation, we could define two different populations of cells. Disparity in the populations could be demonstrated by the observation that B cells in the earlier stage were 81.2% Tac-antigen+, 23.2% B2+, 68.9% transferrin receptor+, and 90.5% HLR-DR+, whereas B cells in the later stage were observed to be less positive for each surface antigen: 36.1% Tac-Ag+, 8.3% B2+, 45.3% transferrin receptor+, and 58.7% HLR-DR+. By adding each factor to both B cell fractions, we also demonstrated functional differences in the two populations. B cells in the earlier stage of activation only differentiated in response to IL 2 or IL 2 + IFN-gamma but not to BCDF, which was in contrast to B cells in the later stage that did not differentiate in response to IL 2 but did differentiate to BCDF. However, B cells in both stages proliferated in response to IL 2 but not to BCDF. Finally, we separated B cells in the later stage into two populations by the Percoll discontinuous gradient centrifugation. Lower density (larger) B cells were observed to proliferate but not to differentiate in response to IL 2, whereas higher density (smaller) B cells were observed to differentiate in response to BCDF. Therefore, we conclude that activated B cells initially become large and gain Tac-Ag and differentiate in response to IL 2 alone as well as the combination of IL 2 and IFN-gamma, whereas later in the more mature stage they become smaller again and differentiate into Ig-secreting cells only in response to BCDF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945860

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta.

Authors:  K D Boehm; M F Kelley; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus.

Authors:  A Kitani; M Hara; T Hirose; K Norioka; M Harigai; W Hirose; K Suzuki; M Kawakami; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

3.  Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle.

Authors:  M Campos; H P Hughes; D L Godson; L M Sordillo; A Rossi-Campos; L A Babiuk
Journal:  Can J Vet Res       Date:  1992-01       Impact factor: 1.310

4.  Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis.

Authors:  K Fujihashi; J R McGhee; C Lue; K W Beagley; T Taga; T Hirano; T Kishimoto; J Mestecky; H Kiyono
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression.

Authors:  A Kitani; M Hara; T Hirose; M Harigai; K Suzuki; M Kawakami; Y Kawaguchi; T Hidaka; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

6.  Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore.

Authors:  P Engel; J Inglés; O de la Calle; T Gallart
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

7.  Abnormal production of B cell growth factor in patients with systemic lupus erythematosus.

Authors:  N Ogawa; M Itoh; Y Goto
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

8.  Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation by mitogens.

Authors:  G Pastorelli; M G Roncarolo; J L Touraine; G Peronne; P A Tovo; J E de Vries
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

9.  Interleukin-2-induced DNA synthesis and immunoglobulin secretion by resting human tonsillar B cells: effects of protein kinase C activation.

Authors:  A Franz; A Bryant; J Farrant
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

10.  Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.

Authors:  T Defrance; B Vanbervliet; J P Aubry; J Banchereau
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.